摘要
目的:探讨知柏地黄丸(熟地黄、山茱萸、山药、知母、黄柏等)治疗甲状腺功能亢进症的疗效及作用机制。方法:将85例甲状腺功能亢进患者随机分为2组,对照组40例单用丙硫氧嘧啶片治疗,治疗组45例,在对照组的基础上加用知柏地黄丸治疗,共治疗12周。分别检测治疗前后患者的心率、体质量、游离三碘甲腺原氨酸(FT3)、游离甲状腺素(FT4)、促甲状腺激素(TSH)、游离脂肪酸、抵抗素、脂联素及瘦素水平。结果:治疗组及对照组均能显著减慢患者心率,增加体质量,减低FT3和FT4,升高TSH(P<0.01);两组间比较,治疗组较对照组差异显著(P<0.01)。治疗组及对照组均能减少游离脂肪酸、抵抗素水平,升高脂联素及瘦素水平;其中游离脂肪酸对照组较治疗前无明显差异(P(0.05),治疗组则有显著性差异(P<0.01);抵抗素则治疗后2组均较治疗前有显著性差异(P<0.05),2组间比较治疗组较对照组差异有显著性(P<0.05)。2组脂联素水平较治疗前均无差异(P(0.05),2组瘦素水平均较治疗前差异明显(P<0.05),2组间比较治疗组较对照组有显著性差异(P<0.01)。结论:联用知柏地黄丸治疗甲亢可改善甲亢患者的血清游离脂肪酸、抵抗素、脂联素及瘦素水平,从而改善甲亢患者的糖脂代谢异常,疗效更佳。
AIM： To investigate the effect and the mechanism of Zhibai Dihuang Pill （Radix Rehmanniae praeparata, Fructus Corni, Rhizoma Dioscoreae, Rhizoma Anemarrhenae, Cortex phellodendri Chinensis, etc. ） on patients with hyperthyroidism. METHODS： Eighty-five hyperthyroid patients were randomly divided into two groups. The control group （40 cases） were treated with propylthiouracil, while the treatment group （45 cases） were treated with propylthiouracil and Zhibai Dihuang Pill; in the 12-week long treatment period, the heart rate, body weight, thyroid free FT3 ,FT4 and TSH and the serum level of FAA, resistin, adiponectin, leptin of patients in both groups were measured. RESULTS： After treatment, the heart rate, the serum of FT3, FT4 decreased and the body weight, TSH increased in both groups（ P 〈 0.01 ）. There was significant difference between Zhibai Dihuang Pill treatment group and the control group（P 〈0.05 or P 〈0.01 ）. The serum level of FAA, resistin and the serum level of adiponectin and leptin decreased in both groups, the serum level of FFA, resistin and leptin in Zhibai Dihuang Pill treatment group were significantly difference compared with the control group （P 〈0.05 or P 〈0.01 ） ,but the serum level of adiponectin made no significant difference between two groups （ P 〉 0.05 ）. CONCLUSION ： Zhibai Dihuang Pill can improve the abnormal metabolism of sugar and fat in patients with hyperthyroidism by its actions on the serum level of FFA, resistin, adiponectin, leptin.
出处
《中成药》
CAS
CSCD
北大核心
2009年第10期1488-1490,共3页
Chinese Traditional Patent Medicine
基金
珠海市科技局资助项目(PC20061081)
